Allergan Press Releases

DUBLIN, June 14, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Thomas C. Freyman will join its Board of Directors effective immediately, as part of the company's ongoing board refreshment process. Mr. Freyman, a former Executive Vice President of Finance and Administration at Abbott Laboratories, brings nearly 40 years of healthcare industry and finance experience to Allergan's Board.

DUBLIN, June 13, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced the release of new topline clinical trial data on Bimatoprost SR, the first-in-class sustained-release, biodegradable implant for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Bimatoprost SR is designed to lower IOP for at least 4 months, achieving clinical goals while freeing patients from daily eye drop regimens.

DUBLIN, June 11, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced positive results from CGP-MD-01, a Phase 2b/3 clinical trial evaluating the efficacy, safety, and tolerability of orally administered atogepant. All active treatment arms of atogepant met the primary endpoint across all doses and dose regimens, with a statistically significant reduction from baseline in monthly migraine/probable migraine (MPM) headache days in patients with episodic migraine treated with atogepant compared with placebo for 12 weeks. Atogepant is Allergan's second orally-administered investigational calcitonin gene-related peptide (CGRP) receptor antagonist in development for migraine prevention.  Atogepant follows ubrogepant, Allergan's first oral investigational CGRP antagonist for the acute treatment of migraine, which reported two positive Phase 3 pivotal trial results earlier this year. Allergan will continue with its phase 3 program for atogepant following discussions with regulatory authorities.

DUBLIN, June 7, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leader in women's healthcare and the maker of Lo Loestrin^® Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), today announced the launch of  'BC Trivia' featuring actress and new ambassador Shay Mitchell – a fun and engaging trivia quiz designed to educate young women about contraceptive options in a familiar way for its bold educational platform, Know Your Birth Control^®.

DUBLIN, June 5, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today issued the following statement in response to a public shareholder letter: Allergan's board of directors and management welcome input from all our shareholders, and take into account their views. Our board and management are committed to creating a world class biopharmaceutical and aesthetics business and driving shareholder returns. The conclusion of our recently completed strategic review is to create a more focused Allergan that concentrates on four therapeutic areas where we have leadership positions and depth and breadth of our products and pipeline, and to pursue a disciplined capital allocation strategy to generate value for shareholders.

DUBLIN, June 5, 2018 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that, in honor of Alzheimer's & Brain Awareness Month, it is teaming up with notable celebrities Scott Conant, Sean Hayes, Helen Hunt, Soleil Moon Frye, Molly Sims and Trista Sutter to shine light on what can be a very challenging time for Alzheimer's caregivers, as part of the company's 'Hold on to Hope' initiative.

DUBLIN, May 30, 2018 /PRNewswire/ -- According to the American Society for Aesthetic Plastic Surgery, Hispanics are a key customer group for in-office medical aesthetic procedures, growing 23.5 percent from 2010 to 2017². This statistic served as a jumping-off point for a conversation about aesthetic treatments, including the CoolSculpting^® treatment, during a May 19 event hosted by Allergan plc (NYSE: AGN) and the #WeAllGrow Latina network. The panel discussion featured Dr. Vivian Bucay, a board-certified dermatologist; Gia Fey, Curveygirls Fitness trainer and creator of Body by Gia; and Ana Flores, Founder and Chief Executive Officer of #WeAllGrow Latina Network, an organization dedicated to leveraging social influence to grow a community of Latinas through online conversation. The CoolSculpting^® treatment is FDA-cleared and clinically proven to eliminate stubborn fat using a patented cooling technology.

DUBLIN, May 29, 2018 /PRNewswire/ -- Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy. Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal placebo capsules instead of active capsules.

DUBLIN, May 16, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will present at the Bernstein 34^th Annual Strategic Decisions Conference in New York, NY. The presentation will begin at 10:00 a.m. Eastern Time on Wednesday, May 30, 2018.

DUBLIN, May 7, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas, Nevada. The presentation will begin at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) on Thursday, May 17, 2018.